Preoperative metabolic dysfunction-associated steatohepatitis (MASH) led to a 27.8% lower percentage excess weight loss (%EWL) compared to non-MASH patients at 12 months post-surgery.
Cohort (n=226)
No
Does the presence of preoperative MASH reduce post-operative weight loss in obese patients undergoing laparoscopic sleeve gastrectomy?
Preoperative MASH is an independent negative predictor of weight loss following laparoscopic sleeve gastrectomy, suggesting these patients experience delayed and reduced weight loss outcomes.
Effect estimate: HR 2.058
Absolute Event Rate: 99.68% vs 129.39%
p-value: p=<0.001
Purpose The impact of metabolic dysfunction-associated steatohepatitis (MASH) on post-operative weight loss outcomes remains unclear. This study aims to investigate the effects of preoperative concomitant MASH on weight loss outcomes and metabolic improvements following laparoscopic sleeve gastrectomy (LSG). Methods A retrospective analysis was performed on the clinical data of 226 patients with obesity who underwent LSG and concurrent intraoperative liver biopsy. Univariate analysis, multivariate analysis, and general linear models were employed to evaluate differences in the dynamic trajectories of post-operative weight loss between the groups. Additionally, Kaplan–Meier survival analysis was utilized to compare the time required to achieve successful weight loss outcomes. Results Preoperative body mass index (BMI) and the presence of MASH were independent negative predictors of percentage excess weight loss (%EWL) and percentage total weight loss (%TWL) ( P 0.01). The post-operative %EWL difference between the two groups reached up to 28.9%. Compared with non-MASH patients, patients with preoperative MASH had a significantly lower cumulative incidence of achieving 80% EWL within 1 year post-operatively (χ 2 = 35.17, P 0.05, HR = 2.058). Conclusion Preoperative MASH is significantly associated with lower post-operative weight loss. Compared to non-MASH patients, patients with MASH experienced a delay in achieving satisfactory weight loss outcomes within the first year after surgery, and this was significantly associated with a lower post-operative %EWL.
Pan et al. (Tue,) conducted a cohort in Metabolic dysfunction-associated steatohepatitis (n=226). Laparoscopic sleeve gastrectomy (LSG) vs. Non-MASH group was evaluated on Percentage Excess Weight Loss (%EWL) (HR 2.058, p=<0.001). Preoperative metabolic dysfunction-associated steatohepatitis (MASH) led to a 27.8% lower percentage excess weight loss (%EWL) compared to non-MASH patients at 12 months post-surgery.